Multimodality treatment in immunocompromised patients with severe COVID‐19: the role of IL‐6 inhibitor, intravenous immunoglobulin, and haemoperfusion

Multimodality treatment in immunocompromised patients with severe COVID‐19: the role of IL‐6 inhibitor, intravenous immunoglobulin, and haemoperfusion

Abstract Cytokine release syndrome (CRS) is known to be associated with severe coronavirus disease 2019 (COVID‐19). Multiple anti‐inflammatory therapies such as tocilizumab, corticosteroids, intravenous immunoglobulin (IVIG), and haemoadsorption or haemoperfusion have been used to combat this life‐t...

Full description

Bibliographic Details
Main Authors: Nophol Leelayuwatanakul, Napplika Kongpolprom, Thitiwat Sriprasart, Vorakamol Phoophiboon, Vorawut Thanthitaweewat, Sarita Thawanaphong, Worawan Sirichana, Naricha Chirakalwasan, Kamon Kawkitinarong, Chanchai Sittipunt, Opass Putcharoen, Leilani Paitoonpong, Gompol Suwanpimolkul, Watsamon Jantarabenjakul, Nattachai Srisawat, Monvasi Pachinburavan
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Respirology Case Reports
Subjects:
COVD‐19
haemoperfusion
IVIG
SARS‐CoV‐2
tocilizumab
Online Access:https://doi.org/10.1002/rcr2.733

Internet

https://doi.org/10.1002/rcr2.733

Similar Items